This article was originally published in The Gray Sheet
Transfer of responsibility for the categorization of commercially marketed in vitro diagnostic (IVD) tests under the Clinical Laboratory Improvement Amendments of 1988 from the Centers for Disease Control and Prevention to FDA is under way, according to a Dec. 30 Federal Register notice. The transfer will permit IVD manufacturers to submit premarket applications and requests for complexity categorizations for the products to one agency. CDC and FDA expect the transfer to be complete by Jan. 31. Until that time, categorization requests should continue to be submitted to CDC
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.